Product Alias

MHC, WT1, RMF, AWT1, GUD, NPHS4GUD, WAGR, WIT-2, WT33

Species

Human

Expression sequence

Gly25-Thr305(HLA-A*02:01),Ile21-Met119(B2M) andpeptide

Accession

A0A140T913(HLA-A*02:01)&P61769(B2M)&RMFPNAPYL

Label

C-His-Avi

Expression system

HEK293

Molecular weight

The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Tris-Bis PAGE result.

purity

> 95% as determined by SDS-PAGE and HPLC.

Endotoxin

< 1.0 EU per μg by the LAL method.

preparation

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.

Appearance

Lyophilized Powder

Biological Activity

【ELISA Data】Immobilized Human WT-1 (HLA-A*02:01) Tetramer, His Tag at 1μg/ml (100μl/Well) on the plate. Dose response curve for Anti-WT-1 (HLA-A*02:01) Antibody, hFc Tag with the EC50 of 14.2ng/ml determined by ELISA. 【SPR Data】 Anti-WT-1 (HLA-A*02:01) Antibody captured on Protein A chip, can bind Human WT-1 (HLA-A*02:01) Tetramer, His Tag with an affinity constant of 0.18nM as determined in a SPR assay

Reconstitution method

Centrifuge before opening the lid. Reconstitute the lyophilized protein with distilled water to a concentration of more than 100 μg/mL. It is recommended to aliquot the protein into the amount required for each experiment when using it for the first time to avoid repeated freezing and thawing.